Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Dr. Harry Spiera Retires after 60 Years in Rheumatology

Kurt Ullman  |  Issue: April 2018  |  April 26, 2018

“What is most remarkable about [Dad] is that he is a triple threat,” Dr. Robert Spiera continues. “He is the quintes­sential clinician, an incredible educator and a leader in academic rheumatology that moved the field forward.”

Retirement Relative Term

Retirement is a relative term, in this case. Although Dr. Spiera is leaving behind personal care, he still plans to attend clinics, go to conferences and stay active in rheumatology.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“We are in a field that is still growing and are just beginning to get a better understanding of rheumatic diseases,” Dr. Spiera says. “[Although] we are doing well now, I think we will be doing so much better in the next 20 to 30 years based on scientific advances and new treatments.”

Many of these advances and treatments were made possible by the contributions made over a nearly 60-year-long career.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Kurt Ullman has been a freelance writer for more than 30 years and a contributing writer to The Rheumatologist for 10 years.

Page: 1 2 3 | Single Page
Share: 

Filed under:Profiles Tagged with:Dr. Harry SpieraPolymyalgia RheumaticaSLE Lupus Foundation

Related Articles

    Two Inflammatory Conditions—Polymyalgia Rheumatica and Giant Cell Arteritis—Share Clinical Connection

    March 1, 2013

    Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) have common clinical and epidemiologic links, but they need not occur synchronously

    New Findings for Polymyalgia Rheumatica & Osteoarthritis

    December 1, 2022

    The Plenary III Session reviewed the results of the SAPHYR trial of sarilumab in PMR patients, as well as the WE-CAN study on the impact of a community-level diet & exercise program on knee pain in patients with knee osteoarthritis.

    Polymyalgia Rheumatica: New Tricks for an Old Disease

    January 29, 2024

    Originally posted Feb. 13, 2023; reposted in conjunction with publication of the PMR supplement to the February 2024 issue of The Rheumatologist. PHILADELPHIA—Polymyalgia rheumatica (PMR) is a chronic inflammatory condition that almost exclusively affects individuals older than 50.1 First described in 1888, PMR has been a recognized rheumatic disease since at least 1957. Diagnosing the…

    Permanent Vision Loss in Late Giant Cell Arteritis

    October 18, 2018

    Patients with polymyalgia rheumatica (PMR) or peripheral arthritis may require extra vigilance during treatment because of a suspected link to giant cell arteritis (GCA) and, potentially, permanent vision loss. “Development of giant cell arteritis after treating polymyalgia or peripheral arthritis: a retrospective case-control study,” a March 2018 study published in The Journal of Rheumatology, suggests…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences